Jul. 29 at 12:57 PM
$MDCX Specific Danger for MDCX ShareholdersIf MDCX runs out of money to fund its late-stage trials, it faces the exact structural risk you described:Asset Carve-Out or Sale: A larger pharmaceutical company could step in and purchase the rights to their main product, SkinJect, for cash.Leftover Shell: The cash from that sale would go directly to pay off institutional lenders, banks, and senior creditors.Total Loss: Because common stock shareholders are at the absolute bottom of the corporate ladder, nothing is left for you. The valuable product is moved elsewhere, and your shares in the remaining empty shell drop to zero.The stock is currently facing immense selling pressure and a strongly bearish trend. If it remains under
$1.00 for too long, it will also face Nasdaq compliance pressure and the threat of delisting, which often forces a reverse stock split—another corporate action that heavily destroys retail investor value.
